• +1 513 549 5911 (U.S.)
  • +44 203 318 2846 (U.K.)

30 mins free consultation for each report        Upto 50% Discounts for Highest selling reports

Intravenous Immunoglobulin Market

Intravenous Immunoglobulin Market Study and Trend Research 2014-2025


REPORT HIGHLIGHT
The intravenous immunoglobulin market is estimated to represent a global market of USD 8,306 million by 2017 with growth rate of 6.3%.  Intravenous immunoglobulin (IVIG) is an antibody-based product that can be administered intravenously. It contains the pooled immunoglobulin G, derived from the plasma. In terms of types, these products are categorized as immunoglobulin A, immunoglobulin G, immunoglobulin M, immunoglobulin D, and immunoglobulin E, divided based on the variety of heavy chain these molecules contain. IVIG therapy is basically indicated to the patients with humoral immunodeficiency or whose body does not produce enough antibodies. IVIG therapy act by providing extra antibodies which last for several weeks and help patients to fight against various infectious diseases. Alternatively, the immunoglobulin therapy can provide through subcutaneous route (as an injection under the skin) or intramuscular route.

Market Dynamics

Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) are preferred for treatment of autoimmune diseases. The growth of this market is primarily attributed to the increasing incidences bleeding and autoimmune disorders, aging population, and development of new treatment indications such as myasthenia gravis. However, high cost coupled with stringent regulations associated with IVIG therapy hampers the market growth over the future period.

Disease Types Takeaway

IVIG therapy is widely used for the treatment of many autoimmune diseases. Based on the disease types, the market is divided as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal motor neuropathy, and others. In 2017, Hypogammaglobulinemia is considered to be the largest market, accounted for the 1.6 billion during the same year. It is an immune disorder, characterized by the low level of immunoglobulin and mature B-lymphocytes and plasma cells. This condition can be treated by the replacement of immunoglobulin by subcutaneous or intravenous therapies with antibiotics. IVIG therapy for the treatment of Congenital AIDS is growing significantly, i.e. 7.9% over the forecast period. In terms of route of administration, intravenous route of administration captured the largest share of the total market, around 80.1% in 2017.

Regional Takeaway

Regionally, North America is considered to be the major market, capturing around 47% share across the year owing to the rise in the incidence of autoimmune diseases. According to the American Autoimmune Related Disease Association, Inc. (AARDA), about 50 million Americans were suffered from autoimmune diseases in the year 2012 and the number is expected to grow over the forecast period.

Developing regions such as Asia Pacific, and Latin America is accounted for the significant revenue share due to the favourable government initiatives. For example, in September 2013, Japanese Ministry of Health, Labour and Welfare have approved Hizentra, subcutaneous immunoglobulin therapy.

Key Vendor Takeaway

Companies such as Shire, Octapharma, CSL. Grifols and others are profiled in a study. Increasing research and development initiatives coupled with growing revenue generation from IVIG business by leading players have attracted many companies to invest in this market. For example, CSL recorded around USD 2,320 million from its immunoglobulin business segment in 2014, up 12% compared to the previous year.

In March 2010, the U.S. FDA approved Hizentra, company’s subcutaneous immunoglobulin product which has contributed strong sale in the U.S. and European market. Strong growth is majorly attributed to its convenience in self-administration along with the introduction of co-pay relief program. In addition to this, the recent approval of Hizentra for treatment of primary and secondary immune deficiencies in Japan coupled with the expansion of bi-weekly administration label in the U.S. market has supported the revenue generation. Furthermore, the company achieved strong growth with Privigen and Carimune sale in the Europe and America respectively.	
TABLE OF CONTENT
1. INTRAVENOUS IMMUNOGLOBULIN MARKET OVERVIEW
1.1. Study Scope
1.2. Base Year
1.3. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Key Market Facts
2.2. Geographical Scenario
2.3. Companies in the Market
3. INTRAVENOUS IMMUNOGLOBULIN KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. INTRAVENOUS IMMUNOGLOBULIN INDUSTRY STUDY
4.1. Company Activity Analysis
4.2. Regulatory Framework Analysis
4.3. Market Attractiveness Analysis
4.4. Value Chain Analysis
5. INTRAVENOUS IMMUNOGLOBULIN MARKET LANDSCAPE
5.1. Market Share Analysis
5.2. Key Innovators
6. INTRAVENOUS IMMUNOGLOBULIN MARKET – BY DISEASE TYPES:
6.1. Overview
6.2. CIDP
6.2.1. Overview
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.3. Hypogammaglobulinemia
6.3.1. Overview
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.4. Congenital AIDS
6.4.1. Overview
6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.5. Immunodeficiency diseases
6.5.1. Overview
6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.6. Chronic Lymphocytic Leukaemia
6.6.1. Overview
6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.7. Myasthenia Gravis
6.7.1. Overview
6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.8. Multifocal motor neuropathy
6.8.1. Overview
6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.9. Others
6.9.1. Overview
6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7. INTRAVENOUS IMMUNOGLOBULIN MARKET – BY ROUTE OF ADMINISTRATION:
7.1. Overview
7.2. Intravenous
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7.3. Subcutaneous
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8. INTRAVENOUS IMMUNOGLOBULIN MARKET– BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.2.3. U.S.
8.2.3.1. Overview
8.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.2.4. Canada
8.2.4.1. Overview
8.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.3. Europe
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.3.3. France
8.3.3.1. Overview
8.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.3.4. Germany
8.3.4.1. Overview
8.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.3.5. Rest of Europe
8.3.5.1. Overview
8.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.4. Asia Pacific (APAC)
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.4.3. China
8.4.3.1. Overview
8.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.4.4. India
8.4.4.1. Overview
8.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.4.5. Rest of APAC
8.4.5.1. Overview
8.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.5. Rest of the World
8.5.1. Overview
8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.5.3. Latin America
8.5.3.1. Overview
8.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.5.4. Middle East and Africa
8.5.4.1. Overview
8.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9. KEY VENDOR ANALYSIS
9.1. Shire
9.1.1. Company Overview
9.1.2. SWOT Analysis
9.1.3. Key Developments
9.2. Octapharma
9.2.1. Company Overview
9.2.2. SWOT Analysis
9.2.3. Key Developments
9.3. CSL
9.3.1. Company Overview
9.3.2. SWOT Analysis
9.3.3. Key Developments
9.4. Grifols
9.4.1. Company Overview
9.4.2. SWOT Analysis
9.4.3. Key Developments
9.5. China Biologics Products, Inc.
9.5.1. Company Overview
9.5.2. SWOT Analysis
9.5.3. Key Developments
*Client can request additional company profiling as per specific requirements
10. 360 DEGREE ANALYSTVIEW
11. APPENDIX
11.1. Research Methodology
11.2. Abbreviations
11.3. Disclaimer
11.4. Contact Us

	List of Tables
Table 1 List of Acronyms
Table 2 Key Market Facts, 2014 – 2025
Table 3 Market Drivers: Impact Analysis
Table 4 Market Restraint: Impact Analysis
Table 5 Market Opportunity: Impact Analysis
Table 6 PESTLE Analysis
Table 7 Porter’s Five Forces Analysis
Table 8 Company Market Share Analysis
Table 9 Global Intravenous Immunoglobulin Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Table 10 Intravenous Immunoglobulin Market, by Disease Types, 2014 – 2025 (USD Million)
Table 11 Intravenous Immunoglobulin Market, by Geography, 2014 – 2025 (USD Million)
Table 12 North America Intravenous Immunoglobulin Market, 2014 – 2025 (USD Million)
Table 13 U.S. Intravenous Immunoglobulin Market, 2014 – 2025 (USD Million)
Table 14 Canada Intravenous Immunoglobulin Market, 2014 – 2025 (USD Million)
Table 15 Europe Intravenous Immunoglobulin Market, 2014 – 2025 (USD Million)
Table 16 France Intravenous Immunoglobulin Market, 2014 – 2025 (USD Million)
Table 17 Germany Intravenous Immunoglobulin Market, 2014 – 2025 (USD Million)
Table 18 Asia Pacific Intravenous Immunoglobulin Market, 2014 – 2025 (USD Million)
Table 19 China Intravenous Immunoglobulin Market, 2014 – 2025 (USD Million)
Table 20 India Intravenous Immunoglobulin Market, 2014 – 2025 (USD Million)
Table 21 Latin America Intravenous Immunoglobulin Market, 2014 – 2025 (USD Million)
Table 22 MEA Intravenous Immunoglobulin Market, 2014 – 2025 (USD Million) List of Figures
Figure 1 Research Methodology
Figure 2 Research Process Flow Chart
Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
Figure 4 Regulatory Framework Analysis
Figure 5 Value Chain Analysis Analysis
Figure 6 Intravenous Immunoglobulin Market, by Disease Types, 2014 – 2025 (USD Million)
Figure 7 Intravenous Immunoglobulin Market, by Geography, 2014 – 2025 (USD Million)

Related Reports

Fomesafen-Market

Global Fomesafen Market Research Report 2019-2023

In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Fomesafen Report by Material, Application, and Geography – Global Fo ...read more

Disposable-Incontinence-Products-Market

Global Disposable Incontinence Products Market Research Report 2019-2023

Incontinence refers to the state where there is loss of voluntary control over the urinary bladder muscles or rectal incontinence. In the context of China-US trade war and global economic volatility a ...read more

Emergency-Cervical-Collar-Market

Global Emergency Cervical Collar Market Research Report 2019-2023

Emergency cervical collars are used as orthopedic braces for patients who have suffered traumatic head or neck injuries, and can be employed in treating chronic conditions. In the context of China-US ...read more

Gene-Therapy-Market

Global Gene Therapy Market Research Report 2019-2023

In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Gene Therapy Report by Material, Application, and Geography – Global ...read more

Non-Destructive-Testing-NDT-Market

Global Non-Destructive Testing (NDT) Market Research Report 2019-2023

The non-destructive testing market is witnessing growth due to increasing demand for new infrastructures and the growing need to renovate the existing aging infrastructure. In the context of China-US ...read more

Choose License Type

Single User - This is a single user license, allowing one specific user access to the product.

Multi User - This is a 1-5 user licence, allowing up to five users have access to the product.

Enterprise User - This is an enterprise license, allowing all employees within your organisation access to the product. The report will be emailed to you.

Cards For Payment
Trusted Badge SSL Certified Premium Quality

Why Choose Us

  • Lowest Price Guarantee
  • We offer the lowest prices for the listed reports
  • Data Security
  • Your data is safe and secure
  • Vast Report Database
  • We have more than 2 Million reports in our database
  • Client Focused
  • Personalized updates and 24*7 support
  • Trusted Source and Quality
  • We only work with reputable partners providing high quality research and support
  • Market Segmentation
  • We provide alternative views of the market to help you identify where the real opportunities lie
  • Bulk Discounts
  • We offer great discounts on purchase of multiple reports

How To Reach Us

Reach out to our most senior Sales Professional- Jay Matthews
   +1 513 549 5911 (US)
          +44 203 318 2846 (UK)
   sales@reportsmonitor.com

Our Clients

Intel Samsung 3M BCG LEK Consulting McKinsey Thyssenkrupp Mogensen BASF IQVIA Hella Oracle Accenture Saint Gobain

Testimonials

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed.
-VP of a Automotive division in Germany

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements
-Product Manager at US based Manufacturer

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process
--Marketing Manager at a pharma company in Belgium

Enquire Before Buying

Need to ask a quick question before buying? Please fill out this short form:

Our Features

Wide Network of Publishers

Wide Network of Publishers

Access to over 1M+ market research reports

Trusted by the Best

Trusted by the Best

50+ Clients in Fortune 500

Competitive Pricing

Competitive Pricing

Our regular promotional offers and discounts make us the most economic seller of market reports

Safe and Secure

Safe and Secure

Your payment details are protected by us.